Formulary amendments June 2026 & horizon scanning July 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments May 2026 & horizon scanning June 2026

wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary amendments April 2026 & horizon scanning May 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in April 2026:

Formulary amendments March 2026 & horizon scanning April 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:

Formulary assessment – levodopa inhalation powder (Inbrija)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

The Formulary Assessment tool for inhaled levodopa can be accessed here

Formulary amendments February 2026 & horizon scanning March 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in February 2026:

Switching from disposable to reusable insulin pens

This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams

The switching from disposable to reusable insulin pens bulletin can be accessed here

Electronic repeat dispensing (eRD): medicines roadmap and outcomes of high eRD uptake

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

This report provides a medicines roadmap to support the uptake and implementation of electronic repeat dispensing (eRD). It also presents the results of an analysis on the impact of high levels of eRD implementation on prescribing volume and hospital admissions.

The eRD medicines roadmap strategic insight report can be accessed here

Formulary amendments January 2026 & horizon scanning February 2026

Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in January 2026:

Principles for embedding pharmacogenomics into NHS medicines governance

Pharmacogenomics (PGx) is a key component of personalised medicine. The purpose of this bulletin is to introduce PGx to medicines committees and working groups and provide considerations for embedding PGx testing into medicines governance structures and processes, supporting the safe and effective use of medicines.

This document was updated on 5th of February 2026 with minor text revisions to improve clarity. 

This publication is open access.